|Bid||6.25 x 1800|
|Ask||7.35 x 1300|
|Day's Range||7.00 - 7.30|
|52 Week Range||6.21 - 15.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.83|
Biopharma Cytokinetics Inc. (NASDAQ: CYTK ) announced a delay in drug studies during its earnings call Thursday, prompting a downgrade by Morgan Stanley. The Analysts Morgan Stanley's Matthew Harrison ...
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of US ...
The South San Francisco, California-based company said it had a loss of 51 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Phase 2 Study of Reldesemtiv in Patients with SMA Showed Potentially Clinically Meaningful Effects on Six Minute Walk Distance and Maximal Expiratory Pressure. Results from Phase 2 Clinical Trial of Reldesemtiv ...
Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.
Cytokinetics, Incorporated (CYTK) today announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) were presented in an oral presentation by John W. Day, M.D., Ph.D., Professor of Neurology and Pediatrics (Genetics), Stanford University, at the 2018 Annual Cure SMA Conference in Dallas. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The study, which examined two dose levels of reldesemtiv, 150 mg or 450 mg twice daily, demonstrated dose-dependent increases in 6MWD in ambulatory patients as measured at both post-baseline time points, week four and week eight.
Cytokinetics, Inc. (CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 11:00 AM EDT at the St. Regis Hotel in New York. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function.
Cytokinetics, Incorporated (CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 Annual Cure SMA Conference in Dallas on June 16, 2018. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Looking to add potential meaningful upside to your portfolio, but unsure where to start? Stocks such as Globant and Cytokinetics are considered to be high growth in terms of howRead More...
Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.
LONDON, UK / ACCESSWIRE / April 30, 2018 / Active-Investors.com has just released a free research report on Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZEAL as the Company's latest news hit the wire. On April 26, 2018, the Company announced that it has successfully concluded the End-of-Phase-2 meeting with the US Food and Drug Administration (FDA) regarding the Phase-3 program for Zealand's long-acting GLP-2 analog, glepaglutide, in short bowel syndrome (SBS) patients.
The South San Francisco, California-based company said it had a loss of 56 cents per share. The biopharmaceutical company posted revenue of $5.3 million in the period. Cytokinetics shares have declined ...
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Cytokinetics Incorporated (NASDAQ:CYTK) as an investment opportunity. Anyone interested inRead More...